IRadimed Corporation
IRMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -15.74 | 1.52 | -3.65 | 13.55 |
| FCF Yield | 0.65% | 0.65% | 0.09% | 0.42% |
| EV / EBITDA | 110.49 | 89.30 | 109.67 | 98.71 |
| Quality | ||||
| ROIC | 5.12% | 5.48% | 4.59% | 5.23% |
| Gross Margin | 77.80% | 78.17% | 76.08% | 76.13% |
| Cash Conversion Ratio | 1.25 | 1.34 | 0.92 | 1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.53% | 9.04% | 10.00% | 11.17% |
| Free Cash Flow Growth | 18.81% | 727.84% | -79.71% | -42.59% |
| Safety | ||||
| Net Debt / EBITDA | -7.36 | -6.69 | -8.94 | -7.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.40 | 0.40 | 0.44 | 0.44 |
| Cash Conversion Cycle | 238.56 | 236.05 | 212.20 | 214.40 |